Inhibrx Biosciences, Inc. (INBX) - Net Assets
Based on the latest financial reports, Inhibrx Biosciences, Inc. (INBX) has net assets worth $36.83 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($177.47 Million) and total liabilities ($140.64 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read INBX liabilities breakdown for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $36.83 Million |
| % of Total Assets | 20.75% |
| Annual Growth Rate | 79.51% |
| 5-Year Change | 77.0% |
| 10-Year Change | N/A |
| Growth Volatility | 784.89 |
Inhibrx Biosciences, Inc. - Net Assets Trend (2016–2024)
This chart illustrates how Inhibrx Biosciences, Inc.'s net assets have evolved over time, based on quarterly financial data. Also explore INBX total assets for the complete picture of this company's asset base.
Annual Net Assets for Inhibrx Biosciences, Inc. (2016–2024)
The table below shows the annual net assets of Inhibrx Biosciences, Inc. from 2016 to 2024. For live valuation and market cap data, see INBX market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $133.58 Million | +207.07% |
| 2023-12-31 | $43.50 Million | -25.07% |
| 2022-12-31 | $58.06 Million | +10.83% |
| 2021-12-31 | $52.38 Million | -30.59% |
| 2020-12-31 | $75.47 Million | +180.66% |
| 2019-12-31 | $-93.57 Million | -62.33% |
| 2018-12-31 | $-57.64 Million | -157.11% |
| 2017-12-31 | $-22.42 Million | -1909.52% |
| 2016-12-31 | $1.24 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Inhibrx Biosciences, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 9688500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | 0.00% |
| Other Components | $239.72 Million | 179.45% |
| Total Equity | $133.58 Million | 100.00% |
Inhibrx Biosciences, Inc. Competitors by Market Cap
The table below lists competitors of Inhibrx Biosciences, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Motus Holdings Ltd
JSE:MTH
|
$1.05 Billion |
|
Shanghai Research Institute of Building Sciences Group Co. Ltd A
SHG:603153
|
$1.05 Billion |
|
Jiangsu Maixinlin Aviation Science & Technology Corp. A
SHG:688685
|
$1.05 Billion |
|
Pet Valu Holdings Ltd
TO:PET
|
$1.05 Billion |
|
Dongguan Mentech Optical & Magnetic Co Ltd
SHE:002902
|
$1.05 Billion |
|
Hagerty Inc
NYSE:HGTY
|
$1.05 Billion |
|
Foshan Golden Milky Way Intelligent Equipment Co Ltd
SHE:300619
|
$1.04 Billion |
|
Bittium Oyj
HE:BITTI
|
$1.04 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Inhibrx Biosciences, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 43,503,000 to 133,584,000, a change of 90,081,000 (207.1%).
- Net income of 1,687,572,000 contributed positively to equity growth.
- Other factors decreased equity by 1,597,491,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $1.69 Billion | +1263.3% |
| Other Changes | $-1.60 Billion | -1195.87% |
| Total Change | $- | 207.07% |
Book Value vs Market Value Analysis
This analysis compares Inhibrx Biosciences, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 13.96x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $-0.25 | $128.79 | x |
| 2017-12-31 | $-1.00 | $128.79 | x |
| 2018-12-31 | $-2.13 | $128.79 | x |
| 2019-12-31 | $-2.56 | $128.79 | x |
| 2020-12-31 | $2.99 | $128.79 | x |
| 2021-12-31 | $1.38 | $128.79 | x |
| 2022-12-31 | $1.45 | $128.79 | x |
| 2023-12-31 | $0.92 | $128.79 | x |
| 2024-12-31 | $9.23 | $128.79 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Inhibrx Biosciences, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1263.30%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 843786.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.35x
- Recent ROE (1263.30%) is above the historical average (22.45%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 0.00% | -124.03% | 0.31x | 0.00x | $-7.34 Million |
| 2017 | 0.00% | -244.55% | 0.46x | 0.00x | $-16.56 Million |
| 2018 | 0.00% | -415.51% | 0.75x | 0.00x | $-25.40 Million |
| 2019 | 0.00% | -565.27% | 0.34x | 0.00x | $-42.04 Million |
| 2020 | -100.22% | -590.54% | 0.09x | 1.90x | $-83.18 Million |
| 2021 | -156.10% | -1147.62% | 0.05x | 2.87x | $-87.01 Million |
| 2022 | -250.14% | -6625.27% | 0.01x | 5.01x | $-151.03 Million |
| 2023 | -554.81% | -13408.94% | 0.01x | 7.08x | $-245.71 Million |
| 2024 | 1263.30% | 843786.00% | 0.00x | 1.35x | $1.67 Billion |
Industry Comparison
This section compares Inhibrx Biosciences, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Inhibrx Biosciences, Inc. (INBX) | $36.83 Million | 0.00% | 3.82x | $1.05 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candid… Read more